Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease - PubMed (original) (raw)
. 2003 Jul 1;12(13):1555-67.
doi: 10.1093/hmg/ddg169.
Jeremy van Raamsdonk, Daniel Rogers, Sarah H Coleman, Rona K Graham, Yu Deng, Rosemary Oh, Nagat Bissada, Sazzad M Hossain, Yu-Zhou Yang, Xiao-Jiang Li, Elizabeth M Simpson, Claire-Anne Gutekunst, Blair R Leavitt, Michael R Hayden
Affiliations
- PMID: 12812983
- DOI: 10.1093/hmg/ddg169
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
Elizabeth J Slow et al. Hum Mol Genet. 2003.
Abstract
An expanded CAG repeat is the underlying genetic defect in Huntington disease, a disorder characterized by motor, psychiatric and cognitive deficits and striatal atrophy associated with neuronal loss. An accurate animal model of this disease is crucial for elucidation of the underlying natural history of the illness and also for testing experimental therapeutics. We established a new yeast artificial chromosome (YAC) mouse model of HD with the entire human HD gene containing 128 CAG repeats (YAC128) which develops motor abnormalities and age-dependent brain atrophy including cortical and striatal atrophy associated with striatal neuronal loss. YAC128 mice exhibit initial hyperactivity, followed by the onset of a motor deficit and finally hypokinesis. The motor deficit in the YAC128 mice is highly correlated with striatal neuronal loss, providing a structural correlate for the behavioral changes. The natural history of HD-related changes in the YAC128 mice has been defined, demonstrating the presence of huntingtin inclusions after the onset of behavior and neuropathological changes. The HD-related phenotypes of the YAC128 mice show phenotypic uniformity with low inter-animal variability present, which together with the age-dependent striatal neurodegeneration make it an ideal mouse model for the assessment of neuroprotective and other therapeutic interventions.
Similar articles
- Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I. Zhang H, et al. Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010. Epub 2008 Apr 16. Neurobiol Dis. 2008. PMID: 18502655 Free PMC article. - Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR. Van Raamsdonk JM, et al. BMC Neurosci. 2006 Dec 5;7:80. doi: 10.1186/1471-2202-7-80. BMC Neurosci. 2006. PMID: 17147801 Free PMC article. - Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM, Fan MM, Fan J, Shehadeh J, Zhang LY, Graham RK, Hayden MR, Raymond LA. Cowan CM, et al. J Neurosci. 2008 Nov 26;28(48):12725-35. doi: 10.1523/JNEUROSCI.4619-08.2008. J Neurosci. 2008. PMID: 19036965 Free PMC article. - Selective degeneration in YAC mouse models of Huntington disease.
Van Raamsdonk JM, Warby SC, Hayden MR. Van Raamsdonk JM, et al. Brain Res Bull. 2007 Apr 30;72(2-3):124-31. doi: 10.1016/j.brainresbull.2006.10.018. Epub 2006 Nov 16. Brain Res Bull. 2007. PMID: 17352936 Review. - Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.
Gil-Mohapel JM. Gil-Mohapel JM. CNS Neurosci Ther. 2012 Jan;18(1):77-86. doi: 10.1111/j.1755-5949.2011.00246.x. CNS Neurosci Ther. 2012. PMID: 21501423 Free PMC article. Review.
Cited by
- Dual effects of neuroprotection and neurotoxicity by general anesthetics: role of intracellular calcium homeostasis.
Wei H, Inan S. Wei H, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Dec 2;47:156-61. doi: 10.1016/j.pnpbp.2013.05.009. Epub 2013 May 28. Prog Neuropsychopharmacol Biol Psychiatry. 2013. PMID: 23721657 Free PMC article. Review. - Real-time imaging of glutamate clearance reveals normal striatal uptake in Huntington disease mouse models.
Parsons MP, Vanni MP, Woodard CL, Kang R, Murphy TH, Raymond LA. Parsons MP, et al. Nat Commun. 2016 Apr 7;7:11251. doi: 10.1038/ncomms11251. Nat Commun. 2016. PMID: 27052848 Free PMC article. - Structural and functional features of medium spiny neurons in the BACHDΔN17 mouse model of Huntington's Disease.
Goodliffe J, Rubakovic A, Chang W, Pathak D, Luebke J. Goodliffe J, et al. PLoS One. 2020 Jun 23;15(6):e0234394. doi: 10.1371/journal.pone.0234394. eCollection 2020. PLoS One. 2020. PMID: 32574176 Free PMC article. - Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay.
Gupta S, Jie S, Colby DW. Gupta S, et al. J Biol Chem. 2012 Mar 23;287(13):9982-9989. doi: 10.1074/jbc.M111.305417. Epub 2011 Dec 20. J Biol Chem. 2012. PMID: 22187438 Free PMC article. - Comparison of mHTT Antibodies in Huntington's Disease Mouse Models Reveal Specific Binding Profiles and Steady-State Ubiquitin Levels with Disease Development.
Bayram-Weston Z, Jones L, Dunnett SB, Brooks SP. Bayram-Weston Z, et al. PLoS One. 2016 May 19;11(5):e0155834. doi: 10.1371/journal.pone.0155834. eCollection 2016. PLoS One. 2016. PMID: 27196694 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases